MedTrace Logo

A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors

NCT01011972 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2018-01-31

No results posted yet for this study

Summary

XMT-1107 has been shown in nonclinical studies to slow the growth of tumors. These effects may result from blocking the growth of new blood vessels that help the tumors survive.

Conditions

  • Neoplasm Metastasis

Interventions

DRUG

XMT-1107

6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops

Sponsors & Collaborators

  • Mersana Therapeutics

    lead INDUSTRY

Principal Investigators

  • Johana Bendell, MD · Sara Cannon Research Institute

  • Geoffrey Shapiro, MD · Dana-Farber Cancer Institute

  • Edward Sausville, MD · University of Maryland, Greenbaum Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01011972 on ClinicalTrials.gov